Corrigendum

Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence

Anna Murphy, Liam J Nestor, John McGonigle, Louise Paterson, Venkataramana Boyapati, Karen D Ersche, Remy Flechais, Shankar Kuchibatla, Antonio Metastasio, Csaba Orban, Filippo Pasetti, Laurence Reed, Dana Smith, John Suckling, Eleanor Taylor, Trevor W Robbins, Anne Lingford-Hughes, David J Nutt, John FW Deakin, Rebecca Elliott and ICCAM Platform

Neuropsychopharmacology (2017) 42, 1925–1926; doi:10.1038/npp.2017.99

Correction to: *Neuropsychopharmacology* (2017) 42, 1049–1057; doi:10.1038/npp.2016.289; published online 25 January 2017

Following publication, the authors reported errors in Table 1. These included an incorrect F-value and *p*-value for the middle frontal gyrus cluster significant in the MID whole-brain drug

Table 1 Results from ROIs and Whole-Brain Analyses for the MID (Top Two Subtables) and GNG (Bottom Two Subtables) Tasks

MID ROI analysis						
Region	Effect of drug	Drug × group interaction			Effect of group	
Ventral striatum	$F(1, 79) = 8.35, p = 0.005, \text{GSK} > \text{PBO}$	$F(2, 79) = 1.31, p = 0.28, \text{NS}$			$F(2, 79) = 3.16, p = 0.048, \text{NS}$	
Ventral pallidum	$F(1, 79) = 30.83, p < 0.001, \text{GSK} > \text{PBO}$	$F(2, 79) = 3.32, p = 0.041, \text{NS}$			$F(2, 79) = 2.01, p = 0.141, \text{NS}$	
Substantia nigra	$F(1, 79) = 7.28, p = 0.009, \text{GSK} > \text{PBO}$	$F(2, 79) = 0.86, p = 0.43, \text{NS}$			$F(2, 79) = 3.29, p = 0.042, \text{NS}$	
MID whole brain						
Contrast	Region	Cluster size	MNI coordinates	F-value	P-value (FWE corrected)	Direction
Main effect of the drug	Left ventral pallidum	11	−15, 5, −10	34.77	0.001	GSK>PBO
	Right middle frontal gyrus	11	30, 29, 29	29.22	0.003	GSK>PBO
	Right cerebellum	9	39, −49, −28	27.81	0.007	GSK>PBO
	Left caudate	19	−15, −1, 20	26.51	0.01	GSK>PBO
Drug × group	Right middle frontal gyrus	6	30, 32, 32	16.59	0.01	GSK>PBO; AD>HC, PD
Main effect of the group	No significant clusters					
GNG ROI analysis						
Region	Effect of drug	Drug × group interaction			Effect of group	
Right inferior frontal gyrus	$F(1, 70) = 1.66, p = 0.20, \text{NS}$	$F(2, 70) = 0.88, p = 0.42, \text{NS}$			$F(2, 70) = 4.45, p = 0.015, \text{PD} > \text{HC}$	
Left inferior frontal gyrus	$F(1, 70) = 0.35, p = 0.56, \text{NS}$	$F(2, 70) = 1.12, p = 0.29, \text{NS}$			$F(2, 70) = 3.49, p = 0.036, \text{NS}$	
Anterior cingulate cortex	$F(1, 70) = 0.99, p = 0.32, \text{NS}$	$F(2, 70) = 1.02, p = 0.37, \text{NS}$			$F(2, 70) = 3.29, p = 0.119, \text{NS}$	
GNG whole brain						
Contrast	Region	Cluster size	MNI coordinates	F-value	p-value (FWE corrected)	Direction
Main effect of the drug	No significant clusters					
Drug × group	No significant clusters					
Main effect of the group	Right midbrain	13	15, −7, −10	19.13	0.003	AD>HC, PD

Abbreviations: GSK, GSK598809 session; PBO, placebo session.

by group interaction contrast. There were also typographical errors and inconsistencies in the abbreviations used to indicate the placebo session. A revised Table 1 is provided with the corrections underscored.

The following additional small errors were found in the Results section.

Page 1052, 'MID fMRI', second paragraph under 'Effects of group and drug: whole-brain analysis', the figure displaying the drug effect within the middle frontal gyrus is Supplementary Figure S5, not S3 as stated.

Page 1052, 'MID fMRI', second paragraph under 'ROI analysis', for the substantia nigra region of interest, the F-value for the exploratory main effect of group comparison using the placebo data should be 4.01, not 5.03. However, the

stated associated *p*-value of 0.022 is correct. (Note that the F-value of 5.03 given earlier in the paragraph for the ventral striatum comparison is correct).

Page 1052, 'GNG fMRI—Effect of Task', under 'ROI analysis', the statistics for the main effect of group within the right inferior frontal gyrus (IFG) should be ' $F(2,70) = 4.45$, $p = 0.015$ ', not ' $F(2,70) = 4.71$, $p = 0.012$ '. The *p*-value for the trend effect within the left IFG should be 0.036, not 0.024. The errors in these GNG ROI statistics appear only on this page; they were presented correctly in the original Table 1.

Page 1055, last paragraph above 'GNG', 'GSK898809' should be 'GSK598809'.

These errors do not alter the conclusions of the report. The authors apologize for any inconvenience.